SYCAI MEDICAL

Sycai Medical

Improving Patient Care Through AI-assisted Detection of Pancreatic Cystic Lesions

Pancreatic cystic lesions can evolve into pancreatic cancer, the 4th leading cause of death by cancer in Europe, and accurate and early detection of these lesions is critical to identify people who may be at risk.[1] That's why Sycai Medical developed a solution to help radiologists detect pancreatic cystic lesions through AI imaging analysis of CT scans. The solution empowers healthcare professionals to provide more precise diagnoses, monitor cystic lesions throughout their treatments, and aid in the prediction of their evolution. This assistive technology can identify, classify, and predict cysts that may be malignant, and cysts that are staying benign. Through the Intel® distribution of OpenVINO™ Sycai Medical is able to make these cystic predictions faster and more accurate, enabling physicians to be more effective, efficient, and to improve patient care.

Key Features

- Hospital PACS Integration
- Zero-clicks AI
- Patient Data Protection
- Lesion Malignancy Prediction

Vertical:
- Health & Life Sciences

Use Cases:
- Human Wellness Monitoring

Country/Geo:
- Eastern Europe
- Western Europe

Learn more:
- The Sycai Medical Website
- Intel Pancreas Cystic Lesions Sycai Blog Post

> *"I believe that SYCAI Medical has a disruptive value proposition focused on anticipating and beating cancer that will become a must in the future of clinical practice. In addition, its price makes it clearly cost/effective, fitting into the budget of any hospital."*
>
> Manel Escobar, MD. Head of Radiology and Imaging Diagnostic in Vall d'Hebrón Hospital and Medical Center Teknon and Quironsalud (Barcelona)

Intel Products and Technologies
- Intel® Distribution of OpenVINO™ Toolkit Product Page
- Intel® Xeon® Scalable Processors Product Page
- Intel® Optimization for PyTorch Introduction

intel®

[1] Digestive Cancers Europe, World Pancreatic Cancer Day, 2022